# US 2023/0057065 A1 · Compositions comprising natural extracts for stimulating the immune response

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0057065 A1
- Document ID: US20230057065A1
- Status: Published application
- Kind: A1
- Application number: 17/642,645
- Filed: 2021-11-11
- Published: 2023-02-23
- Earliest claimed: 2020-11-13
- Assignees: Lebanese Arabian Company for Alternative Therapeutics; Shiban Canada Inc.
- Applicants: Lebanese Arabian Company for Alternative Therapeutics; Shiban Canada Inc.
- Inventors: Abdulhameed Abdulridha K. Al-Shaibani; Abderrahim Maallah
- Web page: https://patentgrep.com/patent/US20230057065A1

## CPC

- A61K 35/644: Beeswax; Propolis; Royal jelly; Honey
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 31/235: having an aromatic ring attached to a carboxyl group
- A61K 31/7024: Esters of saccharides
- A61K 36/54: Lauraceae (Laurel family), e.g. cinnamon or sassafras
- A61K 36/61: Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 37/04: Immunostimulants
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application relates to compositions and dosage forms comprising propolis and tannic acid (sumac powder), and optionally other ingredients such as cinnamon, clove and/or gum arabic. The present application also relates to the use of such compositions or dosage forms for enhancing or boosting the immune response in subjects, for example subjects suffering from infectious diseases such as COVID-19.

## Claims

### Claim 1

A composition comprising from 20% to about 75% (w/w) of propolis and from 10% to 30% (w/w) of tannic acid.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The composition of claim 1, wherein the composition comprises from about 20% to about 40% (w/w) of propolis.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the composition comprises from about 40% to about 75% (w/w) of propolis.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the composition comprises from about 10% to about 25% (w/w) of tannic acid.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the composition comprises from about 15% to about 20% (w/w) of tannic acid.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the composition comprises from about 20% to about 30% (w/w) of tannic acid.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The composition of claim 1, wherein the composition further comprises gum arabic, cinnamon and/or clove.

### Claim 10

(canceled)

### Claim 11 (depends on 9)

The composition of claim 9, wherein the composition comprises about 10% to about 30% (w/w) of gum arabic.

### Claim 12

(canceled)

### Claim 13 (depends on 9)

The composition of claim 9, wherein the composition comprises about 10% to about 30% (w/w) of cinnamon.

### Claim 14

(canceled)

### Claim 15 (depends on 9)

The composition of claim 9, wherein the composition comprises about 1% to about 10% (w/w) of clove.

### Claim 16 (depends on 1)

The composition of claim 1, wherein the composition further comprises at least one carrier or excipient.

### Claim 17 (depends on 16)

The composition of claim 16, wherein the at least one carrier or excipient comprises (i) a binder, and wherein the composition comprises from about 2% to about 20% (w/w) of the binder; and/or (ii) a lubricant, and wherein the composition comprises from about 0.05% to about 3% (w/w) of the lubricant.

### Claim at position 18

18-23. (canceled)

### Claim 24 (depends on 1)

The composition of claim 1, wherein the composition comprises:
Ingredients
% (w/w)
Propolis
50-70%
Tannic acid
20-30%
Magnesium stearate
0.5-2%
Microcrystalline cellulose
5-15%.

### Claim 25

(canceled)

### Claim 26 (depends on 1)

The composition of claim 1, wherein the composition comprises:
Ingredients
% (w/w)
Propolis
20-35%
Tannic acid
14-20%
Gum arabic
15-27%
Cinnamon powder
10-20%
Clove powder
2-8%
Magnesium stearate
0.5-2%
Microcrystalline cellulose
5-15%.

### Claim at position 22

27-28. (canceled)

### Claim 29 (depends on 1)

An oral dosage form comprising the composition of claim 1.

### Claim 30 (depends on 29)

The oral dosage form of claim 29, which is a capsule or a tablet comprising from about 500 mg to about 2 g of the composition.

### Claim at position 25

31-32. (canceled)

### Claim 33 (depends on 1)

A method for enhancing the immune response and/or treating an infection in a subject, the method comprising administering to the subject an effective amount of the composition of claim 1.

### Claim at position 27

34-36. (canceled)

### Claim 37 (depends on 33)

The method of claim 33, wherein the subject suffers from infection or is at risk of suffering from an infection.

### Claim 38

(canceled)

### Claim 39 (depends on 37)

The method of claim 37, wherein the infection is a viral infection.

### Claim 40 (depends on 39)

The method of claim 39, wherein the viral infection is an influenza infection, an RSV infection or a SARS-CoV-2 infection.

### Claim at position 32

41-47. (canceled)
